96 Tests PN: A111119

32 Tests PN: A111119T


45x Ab-conjugated beads (S5P4 - human IFNα2 Ab-bead).

  • 96 Tests PN: A111119A. One vial containing 100 µL of anti-human IFNα2 conjugated to AimPlex Bead S5P4

  • 32 Tests PN: A111119TA. One vial containing 35 µL of anti-human IFNα2 conjugated to AimPlex Bead S5P4

25x Biotin-detection Ab (human IFNα2 Biotin-dAb).

  • 96 Tests PN: A111119B. One vial containing 100 µL of biotinylated anti-human IFNα2.

  • 32 Tests PN: A111119TB. One vial containing 35 µL of biotinylated anti-human IFNα2.

Lyophilized Standard Mix-Human Group 2 Panel A, 10-Plex.

  • 96 & 32 Tests PN: HG2009A. One vial containing lyophilized recombinant human G-CSF, GM-CSF, IFNα2, IL-1α, IL-3, IL-5, IL-7, IL-11, IL-12p40, and IL-13. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits. 

Application: Optimal antibody pair and antigen standard for assaying human IFNα2.  Can be multiplexed with other analytes in Human Group 2.  To be used in conjunction with the AimPlex NR Basic Kit (96 Tests PN: P100001, 32 Tests PN: P100001T) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < 10 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 2: Negligible

  • Sample volume: 15 µL/test


Interferon-alpha (IFN-alpha), also known as leukocyte interferon, IFNA2, IFNA2b, alpha-2a interferon, IFNA, and IFN-alpha-2, represents a group of related but distinct proteins that share over 95% amino acid sequence homology. They are members of the type I interferon family which share a common cell surface receptor composed of two subunits, a 100 kDa ligand-binding subunit (IFN-alpha R2) and a 125 kDa ligand binding and signal transduction subunit (IFN-alpha R1) that is involved both in ligand binding and signal transduction. IFN-alpha has both anti-viral and immunomodulatory activities on target cells.


  1. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Authors: Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, Butfiloski EJ, Sobel ES, Reeves WH, Segal MS; Arthritis Rheum., 2007;56(11):3759-69.

  2. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. Authors: Muhlbauer M, Fleck M, Schutz C, Weiss T, Froh M, Blank C, Scholmerich J, Hellerbrand C.; J. Hepatol., 2006;45(4):520-8.

  3. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Authors: Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J,; Nature, 2012;487(7408):505-9.

  4. Role of microRNA modulation in the interferon-alpha/ribavirin suppression of HIV-1 in vivo. Authors: Abdel-Mohsen M, Deng X, Danesh A, Liegler T, Jacobs E, Rauch A, Ledergerber B, Norris P, Gunthard H, Wong J, Pillai S.; PLoS ONE, 2014;9(10):e109220.